Kerry Rogers, MD, weighs sequencing risk against daily adverse effects like bruising and joint pain that quietly influence BTK inhibitor decisions. On the selection side, Rogers explains why covalent ...
Confirmed Bundibugyo ebolavirus infections reached 1,708 with 580 deaths, increasing from early July counts and prompting WHO’s May 17 PHEIC designation. Unpaid wages and bonuses since mid-May ...
Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...
The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to ...
In a recent podcast, Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, offered a candid account ...
Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care. In part 2 of an interview with The American ...
Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...
ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...
VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes ...
Secret-shopper testing showed 91.8% of online sellers issued GLP-1 RA prescriptions and 69.4% shipped medication, often within one day and sometimes within minutes. Intake workflows commonly lacked ...
AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results